BACKGROUND: Methoxycarbonyl etomidate (MOC-etomidate) is a rapidly metabolized and ultrashort-acting etomidate analog that does not produce prolonged adrenocortical suppression after bolus administration. Its metabolite (MOC-ECA) is a carboxylic acid whose pharmacology is undefined. We hypothesized that MOC-ECA possesses significantly lower pharmacological activity than MOC-etomidate, accounting for the latter's very brief duration of hypnotic action and inability to produce prolonged adrenocortical suppression after bolus administration. To test this hypothesis, we compared the potencies of MOC-ECA and MOC-etomidate in 3 biological assays. METHODS: The hypnotic potency of MOC-ECA was assessed in tadpoles using a loss-of-righting reflexes assay. The ␥-aminobutyric acid type A (GABA A ) receptor modulatory potencies of MOC-ECA and MOC-etomidate were compared by defining the concentrations of each required to directly activate ␣ 1 (L264T)␤ 2 ␥ 2L GABA A receptors. The adrenocortical inhibitory potencies of MOC-ECA and MOC-etomidate were compared by defining the concentrations of each required to inhibit in vitro cortisol production by adrenocortical cells. RESULTS: MOC-ECA's 50% effective concentration for loss-of-righting reflexes in tadpoles was 2.8 Ϯ 0.64 mM as compared with a previously reported value of 8 Ϯ 2 M for MOC-etomidate. The 50% effective concentrations for direct activation of GABA A receptors were 3.5 Ϯ 0.63 mM for MOC-ECA versus 10 Ϯ 2.5 M for MOC-etomidate. The half-maximal inhibitory concentration for inhibiting in vitro cortisol production by adrenocortical cells was 30 Ϯ 7 M for MOC-ECA versus 0.10 Ϯ 0.
M ethoxycarbonyl etomidate (MOC-etomidate) is a rapidly metabolized and ultrashort-acting etomidate analog that does not produce prolonged adrenocortical suppression in rats after bolus administration. 1 In common with remifentanil, esmolol, and remimazolam, it contains a metabolically labile ester moiety that is rapidly hydrolyzed by esterases to form a carboxylic acid metabolite (Fig. 1) . The pharmacological activities of the carboxylic metabolites of remifentanil, esmolol, and remimazolam are orders of magnitude lower than those of their respective parent compounds (4600-fold, 300-to 1600fold, and 300-fold, respectively). [2] [3] [4] [5] [6] However, the pharmacological activity of MOC-etomidate's carboxylic acid metabolite (MOC-ECA) has not been assessed and its potency relative to MOC-etomidate is unknown. We hypothesized that this metabolite possesses significantly lower potency than the parent compound, accounting for the latter's very brief duration of hypnotic action and inability to produce prolonged adrenocortical suppression after bolus administration. This report describes the pharmacology of MOC-ECA and compares it with that of MOC-etomidate in 3 biological assays.
METHODS
All animal studies were conducted with the approval of the Subcommittee on Research Animal Care at the Massachusetts General Hospital, Boston, Massachusetts. Xenopus laevis tadpoles (early prelimb stage) and adult female X laevis frogs were purchased from Xenopus One (Ann Arbor, MI) and housed in our laboratory (tadpoles) or in the Massachusetts General Hospital Center for Comparative Medicine animal care facility (frogs). MOC-etomidate was synthesized by Aberjona Laboratories (Beverly, MA) using our previously published method. 1 MOC-ECA was synthesized in our laboratory as previously described, and its highest aqueous concentration was limited in our studies to 10 mM to assure complete dissolution in aqueous solutions. 7
Tadpole Loss-of-Righting Reflexes
Loss-of-righting reflex (LORR) in X laevis tadpoles was assessed as previously described. 1, 8 In brief, groups of 5 tadpoles were placed in water containing the desired quantity of MOC-ECA and buffered with 2.5 m⌴ Tris HCl (pH ϭ 7.4). Tadpoles were tipped every 5 minutes with a flame-polished pipette until the response stabilized. A tadpole was determined to have LORR if it failed to right itself within 5 seconds after being turned supine. At the end of each study, tadpoles were returned to fresh water to ensure reversibility. MOC-ECA's 50% effective concentration (EC 50 ) for LORR was then determined from the concentration dependence of LORR using the quantal method of Waud. 9
␥-Aminobutyric Acid A Receptor Electrophysiology
Stages 4 and 5 oocytes were obtained as previously described and injected with messenger RNA encoding the ␣ 1 (L264T), ␤ 2 , and ␥ 2L subunits of the human ␥-aminobutyric acid type A (GABA A ) receptor (approximately 40 ng of messenger RNA total at a subunit ratio of 1:1:2). 1 We chose to use ␣ 1 (L264T)␤ 2 ␥ 2L rather than wildtype GABA A receptors to assess the relative potencies of MOC-etomidate and MOC-ECA on GABA A receptors because previous studies have shown that this mutant is very potently and effectively directly activated by anesthetics, which allows for more precise estimation of drug potency when drug solubility is limited. 10 After injection, oocytes were incubated in ND-96 buffer solution (96 m⌴ NaCl, 2 m⌴ KCl, 1 m⌴ CaCl 2 , 0.8 m⌴ MgCl 2 , 10 mM HEPES, pH ϭ 7.4) containing 50 U/mL penicillin and 50 g/mL streptomycin at 17°C for at least 18 hours before electrophysiological experiments.
All electrophysiological recordings were performed using the whole-cell 2-electrode voltage-clamp technique with oocytes voltage clamped at Ϫ50 mV using a Ge-neClamp 500B amplifier (Molecular Devices, Sunnyvale, CA) and perfused with ND-96 buffer with 1 mM EGTA at a rate of 4 to 6 mL/min. Buffer perfusion was controlled using a 6-channel valve controller (Warner Instruments, Hamden, CT) interfaced with a Digidata 1322A data acquisition system (Molecular Devices) and driven by a Dell personal computer (Round Rock, TX). Current responses were recorded using Clampex 9.2 software (Molecular Devices) and processed using a Bessel (8-pole) low-pass filter with a cutoff at 50 Hz using Clampfit 9.2 software (Molecular Devices).
Currents were elicited by application of MOC-etomidate or MOC-ECA (each dissolved in ND-96 buffer with 1 mM EGTA). The recorded peak current amplitudes were normalized to control currents elicited with 1 mM GABA (also dissolved in ND-96 buffer with 1 mM EGTA) in the same oocyte. EC 50 values for direct activation were calculated by fitting a plot of the normalized current amplitude versus MOC-etomidate or MOC-ECA concentration to a Hill equation.
Suppression of Cortisol Synthesis
Suppression of in vitro cortisol synthesis by MOCetomidate and MOC-ECA was quantified as previously described using an in vitro adrenocortical cell (NCI-H295R, ATCC CRL-2128; American Type Culture Collection, Manassas, VA) assay. 8 Briefly, aliquots of cells (10 5 cells/well) were grown in 12-well culture plates with 2 mL growth medium. After reaching near confluence, the growth medium was replaced with an assay medium containing 20 M forskolin (to stimulate cortisol synthesis) and the desired concentration of either MOC-etomidate or MOC-ECA. After 48 hours, 1.2 mL of assay medium was collected from each well, centrifuged, and the cortisol concentration in the supernatant determined using an enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, MN). The cortisol concentrations in the supernatant of wells containing MOC-etomidate or MOC-ECA were normalized to those in control wells without MOC-etomidate or MOC-ECA. The half-maximal inhibitory concentrations for adrenocortical cell inhibition were then calculated by fitting a plot of the normalized cortisol concentration versus MOC-etomidate or MOC-ECA concentration to a Hill equation.
Statistical Analysis
All data are reported as mean Ϯ SD unless otherwise noted. Curve fitting was performed using Igor Pro 6.1 (WaveMetrics, Lake Oswego, OR).
RESULTS
The fraction of tadpoles that had LORR increased with MOC-ECA concentration and at the highest concentration studied (10 mM); 18 of 20 tadpoles had LORR (Fig. 2) . This LORR was reversible because all 52 tadpoles that had LORR in our studies recovered their righting reflexes when returned to water without MOC-ECA. From the MOC-ECA concentration dependence of LORR, the EC 50 for LORR was determined to be 2.8 Ϯ 0.64 mM.
MOC-etomidate and MOC-ECA directly activated ␣ 1 (L264T)␤ 2 ␥ 2L GABA A receptors in a concentrationdependent manner (Fig. 3) . However, the concentration ranges over which this activation occurred differed between the 2 compounds by 2 to 3 orders of magnitude. With MOC-etomidate, this amplitude reached a plateau by 100 M that approximated the amplitude elicited by 1 mM GABA. From the concentration-response relationship, we calculated an EC 50 for direct activation of 10 Ϯ 2.5 M. With MOC-ECA, this amplitude failed to reach a plateau even at 10 mM, the highest concentration studied. From the MOC-ECA concentration-response relationship, we calculated an EC 50 for direct activation of 3.5 Ϯ 0.63 mM with the caveat that this value may somewhat overestimate the true potency of the metabolite because no clear plateau in the response was achieved.
MOC-etomidate and MOC-ECA also suppressed in vitro cortisol synthesis by human adrenocortical cells in a concentration-dependent manner. However, as with direct activation, the concentration ranges over which this action occurred differed between the 2 compounds by 2 to 3 orders of magnitude (Fig. 4) . A fit of the 2 data sets to a Hill equation yielded half-maximal inhibitory concentrations of 0.10 Ϯ 0.02 M for MOC-etomidate and 30 Ϯ 7 M for MOC-ECA.
CONCLUSIONS
MOC-ECA possesses pharmacological activity; however, in each of the 3 biological assays we performed, it was approximately 300-fold less potent than its parent compound MOC-etomidate (Table 1 ). This finding is consistent with our hypothesis that MOC-etomidate's very brief duration of hypnotic action and inability to produce prolonged adrenocortical suppression after bolus administration results from its rapid in vivo hydrolysis to a carboxylic acid metabolite with low pharmacological activity. Forming a metabolite with low potency is particularly important if MOC-etomidate is to be used as a continuous infusion because metabolite accumulation may occur, resulting in a persistent clinical effect if the metabolite possesses significant pharmacological activity. Our studies demonstrating that MOC-ECA is 2 to 3 orders of magnitude less potent than MOC-etomidate in 3 assays suggests that recovery after continuous infusions of MOC-etomidate should occur rapidly in humans. However, clinical trials (or computer simulations) will ultimately be required to gauge the importance of any pharmacological activity of MOC-ECA in humans because the carboxylic acid metabolites of rapidly metabolized drugs may accumulate in renal failure. Under these circumstances, metabolites with even minimal activities might reach concentrations sufficient to produce significant pharmacological effects. When assessed in a variety of assays, the carboxylic acid metabolites GI90291, ASL-8123, and CNS 7054 are similarly orders of magnitude less potent than their respective parent compounds remifentanil, esmolol, and remimazolam. [2] [3] [4] [5] [6] All 4 metabolites contain an identical carboxylic acid moiety whose pK a is 4.8. 12 Therefore, at physiological pH, this moiety is uncharged (i.e., protonated) in 1/400 of all metabolite molecules. This value approximates the potency of MOC-ECA relative to MOC-etomidate, suggesting that MOC-ECA's pharmacological activity (and perhaps those of GI90291, ASL-8123, and CNS 7054) may arise principally from the uncharged, protonated fraction. 
